Symptom Experience of Patients Undergoing Treatment for Multiple Myeloma: a Longitudinal Real-world Electronic Patient-reported Outcomes Study

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2024 Nov 18

PMID 39556121

Authors

Mihir N Patel

Anneli Nina

Brenda Branchaud

Kris W Herring

Suzanne Johnson

Julie Scott

Thomas W LeBlanc

Affiliations

Soon will be listed here.

Abstract

Purpose: Patients with multiple myeloma (MM) experience significant symptom burden. We used a symptom monitoring app to longitudinally characterize the MM treatment experience in detail based on line of therapy (LOT).

Methods: Adults with MM on active treatment completed weekly symptom monitoring surveys. Patients on their 4th LOT or greater were considered heavily pretreated. We characterized moderate to very severe (MOD-VS) symptom prevalence, weekly symptom burden, symptom bother (FACT-GP5), and health-related quality of life (HR-QoL) (EORTC QLQ-C30 Item 30) per LOT.

Results: We considered 109 patients on LOT < 4 and 47 on LOT ≥ 4. The top MOD-VS symptoms were fatigue (71.6% of patients), muscle pain (59.8%), general pain (51.6%), numbness/tingling (48.4%), and insomnia (47.6%). More patients on LOT ≥ 4 experienced numbness/tingling (66.7% vs. 41.3%; OR 2.84, 95% CI 1.27-6.37; p = 0.0098) and fatigue (83.3% vs. 65.6%; OR 2.60, 95% CI 0.96-7.09; p = 0.0557). Some symptoms (fatigue, muscle pain, anxiety) persisted for months among patients on LOT ≥ 4, but patients on LOT < 4 also had unmet longitudinal needs (numbness/tingling, dyspnea). Patients on LOT ≥ 4 had more weeks with ≥ 3 MOD-VS symptoms (27.1% of weeks vs. 15.7%; OR 2.56, 95% CI 1.07-6.08; p = 0.0337) and experienced high symptom bother more often (39.1% of surveys vs. 30.0%; OR 4.23, 95% CI 1.37-13.10; p = 0.0123). HR-QoL was similar between groups.

Conclusion: Heavily pretreated patients experienced greater symptom burden and bother, but patients at earlier LOTs also had unmet needs. Interventions are needed to improve symptom management in MM regardless of LOT, but most pressingly for heavily pretreated patients.

References

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

Johnsen A, Tholstrup D, Petersen M, Pedersen L, Groenvold M . Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009; 83(2):139-48. PMC: 2730555. DOI: 10.1111/j.1600-0609.2009.01250.x. View

Kent E, Ambs A, Mitchell S, Clauser S, Smith A, Hays R . Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2014; 121(5):758-65. PMC: 4546846. DOI: 10.1002/cncr.29119. View

Kumar S, Therneau T, Gertz M, Lacy M, Dispenzieri A, Rajkumar S . Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004; 79(7):867-74. DOI: 10.4065/79.7.867. View

Wang P, Yee C, Gorsh B, Zichlin M, Paka P, Bhak R . Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study. Leuk Lymphoma. 2022; 64(2):398-406. DOI: 10.1080/10428194.2022.2140284. View

Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S . Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016; 175(2):252-264. PMC: 5096152. DOI: 10.1111/bjh.14213. View

Ramsenthaler C, Osborne T, Gao W, Siegert R, Edmonds P, Schey S . The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016; 16:427. PMC: 4937527. DOI: 10.1186/s12885-016-2410-2. View

Batchelder L, Philpott S, Divino V, Boytsov N, Maiese E, Hogea C . Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment. Future Oncol. 2022; 18(25):2843-2856. DOI: 10.2217/fon-2022-0378. View

Ribbands A, Boytsov N, Bailey A, Gorsh B, Luke E, Lambert A . Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA. Support Care Cancer. 2023; 31(6):371. PMC: 10238291. DOI: 10.1007/s00520-023-07836-x. View

10.

Lehmann J, de Ligt K, Tipelius S, Giesinger J, Sztankay M, Voigt S . Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study. J Med Internet Res. 2023; 25:e46017. PMC: 10481208. DOI: 10.2196/46017. View

11.

Brant J, Hirschman K, Keckler S, Dudley W, Stricker C . Patient and Provider Use of Electronic Care Plans Generated From Patient-Reported Outcomes. Oncol Nurs Forum. 2019; 46(6):715-726. DOI: 10.1188/19.ONF.715-726. View

12.

Rajkumar S, Richardson P, San Miguel J . Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015; 126(7):921-2. DOI: 10.1182/blood-2015-05-647636. View

13.

Griffiths P, Peipert J, Leith A, Rider A, Morgan L, Cella D . Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. Support Care Cancer. 2022; 30(4):3613-3623. PMC: 8857159. DOI: 10.1007/s00520-022-06802-3. View

14.

Ramsenthaler C, Kane P, Gao W, Siegert R, Edmonds P, Schey S . Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016; 97(5):416-429. DOI: 10.1111/ejh.12790. View

15.

Gunther M, Hentschel L, Schuler M, Muller T, Schutte K, Ko Y . Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers. BMC Cancer. 2023; 23(1):629. PMC: 10320985. DOI: 10.1186/s12885-023-11115-7. View

16.

Zeng L, Huang H, Liu Y, Ruan C, Fan S, Xia Y . The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis. Support Care Cancer. 2023; 31(5):297. PMC: 10126563. DOI: 10.1007/s00520-023-07759-7. View

17.

Zaleta A, Miller M, Olson J, Yuen E, LeBlanc T, Cole C . Symptom Burden, Perceived Control, and Quality of Life Among Patients Living With Multiple Myeloma. J Natl Compr Canc Netw. 2020; 18(8):1087-1095. DOI: 10.6004/jnccn.2020.7561. View

18.

Nielsen L, Jarden M, Andersen C, Frederiksen H, Abildgaard N . A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017; 99(1):3-17. DOI: 10.1111/ejh.12882. View